Neutral
●
GlobeNewsWire
●
6 months ago
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai and Chief Financial Officer Mark Voll will participate in the Alliance ...